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Therapeutic use of psilocybin has become a focus of recent international research, with preliminary data
showing promise to address a range of treatment-resistant mental health conditions. However, use of
psilocybin as a healing entheogen has a long history through traditional consumption of mushrooms
from the genus Psilocybe. The forthcoming adoption of new psilocybin-assisted therapeutic practices
necessitates identiﬁcation of preferred sources of psilocybin; consequently, comprehensive understanding of psilocybin-containing fungi is fundamental to consumer safety. Here we examine psilocybin
producing fungi, discuss their biology, diversity, and ethnomycological uses. We also review recent work
focused on elucidation of psilocybin biosynthetic production pathways, especially those from the genus
Psilocybe, and their evolutionary history. Current research on psilocybin therapies is discussed, and
recommendations for necessary future mycological research are outlined.
© 2022 The Authors. Published by Elsevier Ltd on behalf of British Mycological Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Corresponding Editor: Dr Ursula Peintner

1. Introduction
Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is an
indole alkaloid originally derived from fungal species primarily in
the genus Psilocybe (Fr.) Kumm. In the body psilocybin is dephosphorylated to form the bioactive agent psilocin. Psilocybin and
psilocin are structurally analogous to the neurotransmitter serotonin (5-hydroxytryptamine). Serotonin and psilocin bind to 5hydroxytryptamine (5-HT2A, 5-HT2C, 5-HT1A, 5-HT1B, and 5-HT1D)
receptors disrupting serotonergic neurotransmission producing
physiological effects (Tyls et al., 2014). Psilocin pharmacodynamics
are reviewed thoroughly elsewhere (Tyls et al., 2014). Recent clinical trial data indicate psychedelics including psilocybin hold
promise in treating patients with depression, anxiety, terminal
illnesses, addiction, and other mental health conditions (e.g., Abbas
et al., 2021; Anderson et al., 2020; Bogenschutz et al., 2015;

* Corresponding author.
E-mail address: jessie.uehling@oregonstate.edu (J.K. Uehling).

Carhart-Harris et al., 2021; Davis et al., 2021; Jacobs 2020; Johnson
et al., 2017).
2. Indigenous history and current traditional uses of
psilocybin
The oldest evidence of the ritualistic consumption of Psilocybe
species is in Mesoamerica and is recorded in the Codex “Yuta
ndez Santiago et al.
Tnoho” or “Vindobonensis Mexicanus I” (Herna
2016, 2017; Jansen et al., 1992). This codex, belonging to the Mixtec
ndez Santiago
culture, was painted in the early 1500s CE (Herna
et al., 2017; Jansen et al., 1992) and depicts a sacred ceremony
where diverse Mixtec deities consume sacred mushrooms prior to
the ﬁrst dawn. While ancient use outside of Mesoamerica has been
speculated (Akers et al., 2011; Samorini 1992), and objects such as
the “mushroom stones” in Guatemala may also suggest a long
history of use (Lowy 1971), these paintings constitute unequivocal
evidence of the importance of entheogenic fungi including Psilocybe species in the Mesoamerican worldview prior to the arrival of
ndez Santiago et al., 2017). Despite the
the Spanish (Herna

https://doi.org/10.1016/j.funbio.2022.01.003
1878-6146/© 2022 The Authors. Published by Elsevier Ltd on behalf of British Mycological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Psilocybin usage differs by region and includes a long history of
whole mushroom consumption in Mesoamerica as detailed above.
There has been a more recent history of mushroom and sclerotia
(‘truffels’) consumption in Jamaica (Lowe et al., 2021) and the
Netherlands (van Amsterdam et al., 2011). The consumption of
‘trufﬂes’ from Psilocybe mexicana and Psilocybe tampanensis, species
originally described in peer-reviewed literature from Oaxaca,
n and Pollock 1978),
Mexico (Heim 1957) and Florida, USA (Guzma
surged in popularity following the 2008 ban of fresh mushroom
sales in the Netherlands (Illana-Estebad 2011). Preliminary evidence indicates that the majority of cultivated psilocybinproducing fungi are Psilocybe cubensis isolates, though substantial
morphological variety between cultures exists, as demonstrated in
a recent analysis of 76 separate P. cubensis strains (McKernan et al.,
2021b).

prohibition of hallucinogenic mushroom consumption by the
Spanish inquisition, the use of Psilocybe species continues to this
day in Mexican ethnic groups such as the Chatins, Chinantecs,
Matlazincs, Mazatecs, Mixes, Nahuatls, Purepechs, Totonacs, and
n 2008; Ramírez-Cruz et al., 2006). Fifty-seven
Zapotecs (Guzma
hallucinogenic Psilocybe species have been described in Mexico
(Ramírez-Cruz et al., 2006); from these, 35 species and 9 varieties
have been reported to be used by ethnic groups and mestizos
mainly in central and southern Mexico. According to modern species concepts, these 44 taxa correspond to 14 currently valid species
s-Pe
rez et al., 2021; Guzma
n 2008) (Table 1).
(Corte
For many indigenous people of Mexico, these mushrooms are
n 2003; Guzma
n et al.,
part of a sacred and ancient tradition (Guzma
ndez Santiago et al. 2016, 2017). Curandera María
2009; Herna
Sabina was the ﬁrst person to enable observation of ritualistic
fungal practices by western scientists, despite hundreds of years of
colonial efforts to eradicate these practices (Heim and Wasson
1958; Wasson 1957). Although María Sabina conditioned her
knowledge sharing with an anonymity clause, and Wasson
respected her request initially (Wasson 1957), he later published
her actual identity in other works (Wasson 1959). Subsequently, up
until her death in 1985 at the age of 91, María Sabina was inundated
with requests from foreigners to partake in the mushroom ceremonies “out of curiosity” or to “ﬁnd God,” and observed that before
Wasson the mushrooms had only been used to treat the sick
(Echevarría 1979).
Contemporary syncretic rituals and ceremonies combining
Mesoamerican and Catholic elements are based in Psilocybe species
consumption and used to treat both spiritual and physical illness
(Guzm
an et al., 2009). Psilocybe mushrooms induce hallucinations
and synesthesia resulting in a trance-like experience that is
thought to allow dissociation of the soul from the body. As a result,
bodily ailment diagnoses, introspection, self-healing, and revelation of lost persons’ locations can be facilitated by traditional
doctors or shamans. While practices vary between indigenous
n 2008; Herrera 2007), in general ceremonies are
groups (Guzma
always done with care at night in a quiet place guided by an elder or
shaman, no meals, alcohol, medicine or drugs are taken in advance,
n 2003, 2008). In
and travel is discouraged for a week after (Guzma
addition to these metaphysical applications, Psilocybe mushrooms
are traditionally used by indigenous communities to treat anxiety,
rheumatism, and as analgesics to relieve toothaches and stomach
lez and Moreno-Fuentes 2014; Guzm
pain (Bautista-Gonza
an et al.,
2009) (Table 1).
Given the ethnic groups that use Psilocybe mushrooms, their
geographic spread, and their applications, the most culturally
important hallucinogenic species of Psilocybe are Psilocybe aztecorum, Psilocybe caerulescens, Psilocybe cubensis, Psilocybe mexicana,
lez and Moreno-Fuentes
and Psilocybe zapotecorum (Bautista-Gonza
s-Pe
rez et al., 2021; Guzma
n 2008; Ramírez-Cruz et al.,
2014; Corte
2006). In addition, endemic species from Mexico with locally
restricted use include Psilocybe candidipes, Psilocybe cordispora,
Psilocybe fagicola, Psilocybehoogshagenii, Psilocybe muliercula, Psilocybe sanctorum, and Psilocybe subcubensis (Table 1). These genetic
resources, their traditional uses and surrounding culture constitute
a biocultural heritage of Mexican indigenous groups protected by
the Nagoya Protocol. The Nagoya Protocol on Access to Genetic
Resources and the Fair and Equitable Sharing of Beneﬁts Arising
from their Utilization is a supplementary agreement to the
Convention on Biological Diversity to which Mexico is signatory
(Secretariat of the Convention on Biological Diversity, 2011).
Consequently, and to avoid international prosecution, careful
consideration including national origin evaluation should be used
to identify strains for commercial development.

2.1. Global diversity of psilocybin producing fungi
Psilocybin and psilocin biosynthetic production has been
documented in a polyphyletic assemblage of species of the mushroom genera Conocybe Fayod, Galerina Earle, Gymnopilus P. Karst.,
l., Pholiotina Fayod, Pluteus Fr.,
Inocybe (Fr.) Fr., Panaeolus (Fr.) Que
and Psilocybe (Fr.) Kumm (Halama et al., 2014; Reingardiene et al.,
2005; Reynolds et al., 2018). Psilocybin has also been reported in
Massospora platypediae R.S. Soper and M. levispora R.S. Soper,
though their genomes lack Psi genes found in the characterized
biosynthetic pathway of (Fricke et al. 2017; Boyce et al., 2019). In
total, there are species from at least eight currently recognized
n
genera of fungi that produce psilocybin and psilocin (Guzma
2009; Lincoff and Mitchel 1977; Stamets 1996).
The majority of known psilocybin-producing fungi belong to the
genus Psilocybe sensu stricto (s.s.), from which psilocybin and psilocin were ﬁrst isolated (Hofmann et al., 1958). The genus Psilocybe
sensu lato (s.l.) is paraphyletic, with the psilocybin-producing
species and the psilocybin-deﬁcient species forming two nonsister monophyletic clades (Moncalvo et al., 2002). The latter
group was segregated from Psilocybe into the resurrected genus
Deconica (W.G. Sm.) P. Karst (Redhead et al., 2007), although the
assignment of the known species of Psilocybe s.l. to the newly
deﬁned genera remains incomplete. The most comprehensive and
recent study of the phylogenetic relationships in Psilocybe s.s. was
conducted by Ramírez-Cruz et al. (2013). In this work, three gene
regions (5.8S, LSU, and rpb1) were employed to resolve many, but
not all, of the relationships among the species sampled. Later
phylogenetic and biochemical work has shown that appropriately
designated Psilocybe fuscofulva (¼ Psilocybe atrobrunnea) does not
produce psilocybin (Borovi
cka et al., 2015), suggesting potential
loss of production in select lineages.
The genus Psilocybe is now estimated to contain over 300 spen 2005; He et al., 2019a).
cies and is distributed worldwide (Guzma
Systematic surveys for Psilocybe are entirely lacking for many regions of the world. All described species, except the enigmatic
secotioid Psilocybe weraroa, from New Zealand (Borovi
cka et al.,
2011), are fungi which produce pileate-stipitate, agaricoid basidiomata (Fig. 1). Salient macromorphological features for the majority of Psilocybe species include dark purple-brown basidiospores,
the presence of an annulus that can be senescent, and blue bruising
on the stipe, pileus, and mycelium upon contact. All currently
described Psilocybe species are assumed to be saprotrophic and
found on a diversity of substrates including herbivore dung,
grasses, roots, wood, and soil (Singer 1958; Stamets 1996).
309
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Table 1
Species of Psilocybe used in ceremonies and traditional medicine in Mexico.
Current name

Synonyms

Traditionally used by

Traditional use

Distribution

Psilocybe aztecorum R.
Heim

Psilocybe aztecorum var. bonetii
n) Guzm
(Guzma
an
n
Psilocybe bonetii Guzma
Psilocybe quebecensis Ola'h & R.
Heim
n, FrancoPsilocybe bispora Guzma
Mol. & Ram.-Guill.
Psilocybe caerulescens var. albida
R. Heim
Psilocybe caerulescens var.
mazatecorum R. Heim
Psilocybe caerulescens var. nigripes
R. Heim
Psilocybe caerulescens var.
ombrophila R. Heim
Psilocybe caribaea Guzm
an, T.J.
Baroni & F. Tapia
n
Psilocybe heliconiae Guzma
Psilocybe mazatecorum R. Heim
Psilocybe mixaeensis R. Heim
Psilocybe subannulata E. Horak &
Guzm
an
n
Psilocybe villarrealiae Guzma
Psilocybe weilii Guzm
an, Stamets
& F. Tapia
n
Psilocybe wrightii Guzma

Nahuatls, central Mexico

Analgesic, soul healing,
divinatory and diagnostic,
antirheumatic

Canada to central Mexico

Psilocybe caerulescens
Murrill

Psilocybe candidipes Singer
& A.H. Sm.
Psilocybe cordispora R.
Heim
Psilocybe cubensis (Earle) Psilocybe cubensis var.
Singer
caerulescens (Pat.) Singer & A.H.
Sm.
Psilocybe cubensis var. cyanescens
(Murrill) Singer & A.H. Sm.
Stropharia cubensis Earle
Psilocybe fagicola R. Heim Psilocybe fagicola var.
emend. Guzm
an
Mesocystidiata Guzm
an
Psilocybe wassoniorum Guzm
an &
Pollock
Psilocybe hoogshagenii R. Psilocybe hoogshagenii R. Heim
n & A.
Heim ex Guzma
s-Pe
rez
Corte
n & S.H.
Psilocybe mexicana R.
Psilocybe armandii Guzma
Heim
Pollock
Psilocybe galindoi Guzm
an
n
Psilocybe pileocystidiata Guzma
& Ram.-Guill.
n,
Psilocybe subacutipilea Guzma
Saldarr., Pineda, G. García & L.-F.
zquez
Vela
Psilocybe muliercula
Psilocybe angustipleurocystidiata
Singer & A.H. Sm.
Guzm
an
Psilocybe mexicana var. brevispora
Heim
Psilocybe wassonii R. Heim
Psilocybe sanctorum
Guzm
an
Psilocybe subcubensis
Guzm
an
Psilocybe yungensis Singer Psilocybe acutissima R. Heim
n
& A.H. Sm.
Psilocybe chiapanensis Guzma
Psilocybe isauroi Singer
Psilocybe subyungensis Guzm
an
Psilocybe yungensis var. diconica
Singer & A.H. Sm.
Psilocybe zapotecorum R. Psilocybe aggericola Singer & A.H.
n
Heim emend. Guzma
Sm.
Psilocybe aggericola var. alvaradoi
Singer
Psilocybe barrerae Cifuentes &
Guzm
an
Psilocybe barrerae Cifuentes &
n
Guzm
an emend. Guzma

Analgesic, soul healing,
Chatins, Mazatecs, Mixes, Nahuatls,
pecha, Totonacs, Zapotecs, central and divinatory and diagnostic
Pure
southern Mexico

USA, Mexico, Ecuador,
Venezuela, Argentina, Brazil,
and the Caribbean

Mazatecs, southern Mexico

Mexico

Mazatecs, Mixes, Totonacs, southern
Mexico
Chatins, Mazatecs, Mixes, Nahuatls,
Zapotecs, central and southern Mexico

Soul healing, divinatory and
diagnostic
Soul healing, divinatory and
diagnostic
Analgesic, soul healing,
divinatory and diagnostic

Nahuatls, Totonacs, Central and southern
Mexico

Soul healing, divinatory and Mexico
diagnostic

Chinantecs, Mazatecs, Mixes, Zapotecs,
southern Mexico

Anxiolytic, analgesic, soul
healing,

Mexico, Colombia

Chatins, Chinantecs, Mazatecs, Mixes,
Nahuatls, Zapotecs, central and southern
Mexico

Soul healing

Mexico, Guatemala, Costa Rica

Nahuatls, Matlazincs, central Mexico

Anxiolytic, analgesic, soul
healing, divinatory and
diagnostic

Mexico

Anxiolytic, analgesic, soul
healing
Chatins, Mazatecs, Mixes, Nahuatls, central Analgesic, soul healing,
and southern Mexico
divinatory and diagnostic
Mazatecs, southern Mexico
Analgesic, soul healing,
divinatory and diagnostic

Mexico

Chatins, Mazatecs, Totonacs, Zapotecs,
southern Mexico

USA, Mexico, Costa Rica,
Colombia, Argentina, and Brazil

Matlazincs, central Mexico

310

Analgesic, soul healing,
divinatory and diagnostic

Mexico
America, from Canada to
Argentina, Europe, Asia, and
Australia

Mexico
Mexico, Costa Rica, Colombia,
Argentina, and Brazil
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Table 1 (continued )
Current name

Synonyms

Traditionally used by

Traditional use

Distribution

n
Psilocybe bolivarii Guzma
Psilocybe candidipes Singer & A.H.
Sm.
n
Psilocybe chaconii Guzma
Psilocybe microcystidiata Guzm
an
& Bononi
Psilocybe pseudozapotecorum
Guzm
an
n
Psilocybe sanctorum Guzma
Psilocybe subzapotecorum
Guzm
an
Psilocybe zapotecorum f. elongata
R. Heim
Psilocybe zapotecorum R. Heim
Psilocybe zapotecorum var.
n & Bononi
ramulosum Guzma
n (2008), Bautista-Gonz
s-Pe
rez et al. (2021), Index Fungorum (http://www.
Data from: Ramírez-Cruz et al. (2006), Guzma
alez and Moreno-Fuentes (2014), Corte
indexfungorum.org/names/names.asp), and Mycobank (https://www.mycobank.org/) repositories.

3. Psilocybin production mechanisms

3.1. Biosynthesis & biochemistry of psilocybin

Psilocybin is a natural secondary metabolite produced by several
fungal species. Traditional ceremonial utilization includes consumption of whole fresh or dried mushrooms. However, fungi can be
cultivated in numerous ways, and modern efforts to produce psilocybin vary. Potential sources for obtaining psilocybin products
include (1) in vitro enzymatic biosynthesis (Fricke et al. 2019a,
2020); (2) hemi-/semisynthetic or total synthesis (Kargbo et al.,
2020; Shirota et al., 2003); (3) artiﬁcial production of psilocybin in
cell culture using biotechnologically modiﬁed genetic model organisms (Adams et al., 2019; Milne et al., 2020); or (4) cultivation of
fungal tissues such as hyphae, mushrooms, and sclerotia, also known
pez et al., 2018; van Amsterdam et al., 2011).
as ‘trufﬂes’ (Rosero Ye
When utilizing in vivo whole organism-based psilocybin production, it becomes essential to sequence genomic loci considered
to be species-level barcodes to accurately identify fungi. The Internal Transcribed Spacer (ITS) region of ribosomal DNA (rDNA) is
the current gold standard for genetic species-level barcoding, but
its ability to resolve species still bears limitations (Tremble et al.,
2020; Yahr et al., 2016). ITS sequences for many Psilocybe species
and other fungi that produce psilocybin are available in public data
repositories such as GenBank, the DNA sequence repository operated by the National Center for Biotechnology Information (NCBI).
However, accurate species-level identiﬁcation of GenBank DNA
sequence data accessions can be variable, uncertain, and
misleading due to several factors. Generating sequences from
misidentiﬁed specimens, mislabeled sequence data accessions, and
the scarcity of authority-curated, type-specimen-based authenticated sequence deposition contribute to the stratiﬁcation of GenBank data quality (Hofstetter et al., 2019). Accurate identiﬁcation of
fungal species is therefore reliant on sometimes subtle macro- and
micromorphological features and genetic comparison to databased
reference sequences of varying quality.
There is notable variability in psilocybin content from species to
species and even between mushrooms in the same fruiting ﬂush
(Andersson et al., 2008; Kamata et al., 2005; Stríbrný et al., 2003;
van Amsterdam et al., 2011). Psilocybe species can vary in psilocybin
content from 0.01 to 2.40% by dry weight (Beug and Bigwood 1982;
Kamata et al., 2005). This natural variation across mushroom species, tissues, and fruitings (Beug and Bigwood 1982) coupled with a
n
historical focus on dry mushroom weight based dosing (Guzma
2009) has led to challenges in comparing mushroom consumption experiences and clinical trial data.

Psilocybin is synthesized by four spatially clustered genes coding enzymes that catalyze reactions for the conversion of tryptophan to psilocybin (Fig. 2) (Fricke et al., 2017; Reynolds et al., 2018).
The genes involved in psilocybin biosynthesis, or the Psi genes,
occupy an ~11e22 kilobase genomic region that includes four genes
encoding the biosynthetic enzymes (PsiD, PsiK, PsiM, PsiH) and one
gene that encodes a putative solute transporter (PsiT) of unknown
function (Blei et al., 2018; Demmler et al., 2020; Fricke et al. 2017,
2019b, 2020; Lenz et al., 2021; Torrens-Spence et al., 2018) that is
co-inherited with the cluster (Reynolds et al., 2018). According to
Fricke et al. (2017), psilocybin biosynthesis begins when tryptophan is decarboxylated by PsiD to form tryptamine. Tryptamine is
then hydroxylated on the 4-position of the indole backbone by the
cytochrome P-450 monooxygenase, PsiH, to form 4hydroxytryptamine. The hydroxyl group of 4-hydroxytryptamine
is next phosphorylated by PsiK to form norbaeocystin. Iterative
methylation of the amine by PsiM then forms baeocystin, and then
psilocybin. Psilocin is derived from the spontaneous dephosphorylation of psilocybin and can be converted back to psilocybin by
PsiK.
The psilocybin biosynthetic pathway produces intermediates
including the tryptamines baeocystin and norbaeocystin (Fig. 2)
(Fricke et al., 2017). In addition to psilocybin and related tryptamines, some Psilocybe species also biosynthesize b-carbolines
(e.g., harmane, harmine, norharmane), which inhibit the monoamine oxidase (MAO) family of enzymes responsible for degradation of serotonin, psilocybin, and related chemicals (Blei et al.,
2020; Lenz et al., 2021). The simultaneous production of b-carboline compounds in some Psilocybe species has been noted to differ
between mycelia and mushrooms tissues (Blei et al., 2020).
3.2. Genomic resources & evolutionary history of Psi gene cluster
Genomic resources, including assembled genomic contigs, unassembled whole genome sequencing data, and transcriptome
data, are available in NCBI GenBank and the Sequence Read Archive
(SRA). Other sources of genomic data for psilocybin-producing
fungi are available through MycoCosm (Grigoriev et al., 2014)
developed by the Joint Genome Institute, or as supplemental data
associated with publications (e.g. Awan et al., 2018). A high-quality
draft assembly of a strain of P. cubensis (McKernan et al., 2021a) is
also available for comparative genomic analyses through CoGe
311
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Fig. 1. Psilocybe species diversity. Basidiomata of (A) Psilocybe serbica (jonagruska, CC-BY-SA 3.0), (B) P. mescalenroensis (Alan Rockefeller, CC BY-SA 4.0), (C) P. cubensis (Ricardo
Arredondo, CC BY-NC), (D) P. ovoideocystidiata (Shroomydan, CC-BY-SA 3.0), (E) P. allenii (Alan Rockefeller, CC-BY-SA 3.0), (F) P. azurescens (Shroom360, CC BY-SA 3.0), (G)
P. cyanescens (Alan Rockefeller, CC BY-SA 3.0), (H) P. subaeruginosa (ericos_bob, CC BY-SA 3.0), (I) P. angulospora (Inski, CC BY-NC-SA), (J) P. baeocystis (Caleb Brown, CC-BY-SA 3.0), (K)
P. pelliculosa (Scottdarbey, CC-BY-SA 3.0), (L) P. semilanceata (Alan Rockefeller, CC-BY-SA 3.0), (M) P. hoogshagenii (Brayan Coral Jaramillo, CC BY-SA 3.0), (N) P. mexicana (Alan
Rockefeller, CC BY-SA 4.0), (O) P. neoxalapensis (David Morales, CC-BY-NC 4.0), (P) P. zapotecorum (Alan Rockefeller, CC-BY-SA 3.0). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the Web version of this article.)

instances of convergent evolution of a psilocybin pathway and/or
gene cluster have since been documented (Boyce et al., 2019). The
presence of psilocybin in cicadas parasitized by Massospora spp.
that lack the canonical biosynthetic gene cluster (Boyce et al., 2019)
suggests the possibility multiple independent origins of psilocybin
biosynthesis. Similarly, in a publication pre-print (Awan et al., 2018)
reported there is no evidence in Inocybe corydalina for orthologs of
the core psilocybin biosynthesis genes of the characterized psilocybin biosynthetic gene cluster. Instead, it was suggested that a
different cluster of genes predicted to encode enzymes, each with
catalytic activity similar to a psilocybin biosynthetic steps evolved
convergently (Awan et al., 2018).

(Lyons and Freeling 2008). ITS sequences are available for over 60
valid Psilocybe species. In total, genomic data is available for seven
psilocybin containing species, with hyphae and basidiomata transcriptomes available for two of these (Supplemental Table 1). These
data have enabled insights into the evolutionary history of the Psi
genes and fungi which contain them (Reynolds et al., 2018).
Initial phylogenetic analyses of the Psi gene cluster suggested it
originated in a common ancestor of Psilocybe and Gymnopilus
(Reynolds et al., 2018). Outside of the mentioned mushroom lineages, close homologs of all psilocybin genes are only currently
known in the crust-forming fungal family, Atheliaceae, but the
genes are not clustered, and psilocybin has not been detected in
this family (Konkel et al., 2021; Reynolds et al., 2018). At least two
312
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Fig. 2. Enzymatic biosynthesis pathway of psilocybin and psilocin from tryptophan as elucidated and conﬁrmed by in vitro assays by Fricke et al. (2017).

function of psilocybin may be due to the potentially toxicity of the
oligomers that are produced upon injury, while the psychoactive
properties of psilocybin/psilocin in humans may be secondary or
incidental.

Phylogenetic evidence suggests the presence of the psilocybin
gene cluster in some distantly related mushroom genera such as
Conocybe, Panaeolus, and Pluteus was the result of horizontal gene
transfer (HGT) (Awan et al., 2018; Reynolds et al., 2018). Species
with the most similar clusters shared ecological habits (e.g., dungdecaying, wood-decaying), and this taken together with the conﬂict
with expected species relationships, may suggest spatial proximity
is a facilitating factor in HGT. However, further taxon sampling and
genomic analyses are needed to unequivocally evaluate this hypothesis, and the mechanism(s) of HGT between mushroomforming fungi are not known. Some genes in the Psi gene cluster
vary in copy number, suggesting differential evolutionary pressures
may act on parts of the psilocybin biosynthetic pathway (Reynolds
et al., 2018).
The ecological function(s) of psilocybin/psilocin remains uncertain. The neuroactive properties of these chemicals have led to
speculation about their potential role as antifeedants or defenses
targeting mycophagous insects and invertebrates (Reynolds et al.,
2018), although empirical evidence is still lacking. However, psilocybin or psilocin may not be the primary compound for a hypothetical defense mechanism. Lenz et al. (2020) recently found that
the chemical structure corresponding to the blue pigment characteristic of some Psilocybe species results from damaged and senescent cells. This pigment is derived from linkage of psilocin
monomers, generated by a dephosphorylase, into short chains by
the release of a laccase enzyme (Lenz et al., 2020). The ecological

4. Extraction and quantiﬁcation of psilocybin
The ﬁrst extractions of psilocybin were completed in the 1950s
utilizing polar solvents including methanol, chloroform, and wateralcohol mixtures (Heim and Wasson 1958; Hofmann et al., 1958,
1959). Albert Hoffman and his research team isolated psilocybin
and psilocin from dried, powdered tissues of P. cubensis and
P. mexicana (Heim and Wasson 1958; Hofmann et al., 1958, 1959).
After redissolving dried residues in a butanol-water mixture and
chromatographic separation on a cellulose column, they crystalized
psilocybin and elucidated the structure by employing a range of
spectroscopic analyses. Later, these structural analyses were
conﬁrmed through the ﬁrst psilocybin synthesis by Hofmann's
team in Troxler et al. (1959).
Puriﬁcation of psilocybin has been carried out using a range of
methodologies (Andersson et al., 2008). Psilocybin can be isolated
from fungal tissues using solid phase extraction (SPE) column
chromatography, in which molecules are separated based on polarity using cartridges packed with a solid stationary phase and
solvents with variable polarity. Due to the high relative polarity of
both psilocybin and psilocin, reverse-phase chromatography
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Grifﬁths et al., 2016; Grob et al., 2011), obsessive-compulsive disorder (Jacobs 2020; Moreno et al., 2006), smoking cessation
(Garcia-Romeu et al., 2014; Johnson et al. 2014, 2017), and alcoholism (Bogenschutz et al., 2015). In addition, a clinically meaningful change was seen in psilocybin-assisted group therapy for
demoralization in older long term AIDS survivors (Anderson et al.,
2020).
Major Depressive Disorder symptoms decreased following psilocybin administration coupled with psychological support in a
phase 2 controlled trial that compared psilocybin with the selective
serotonin reuptake inhibitor (SSRI) escitalopram utilizing the Quick
Inventory of Depressive SymptomatologyeSelf-Report (QIDS-SR16) (Carhart-Harris et al., 2021). This group found that the primary
outcome, deﬁned as mean (±SE) change from baseline QIDS-SR-16
score did not signiﬁcantly differ between groups, and that psilocybin therapies had similar effectiveness in lowering MDD symptoms. A second study found that MDD symptoms decreased
following psilocybin and supportive psychotherapy as measured by
GRID-Hamilton Depression Rating Scale (GRID-HAMD) scores in a
randomized clinical trial (Davis et al., 2021). Obsessive Compulsive
Disorder symptoms also were seen to decrease following psilocybin
assisted therapies measured by the Yale-Brown ObsessiveCompulsive Scale (YBOCS) in a modiﬁed double-blind dose escalation study (Moreno et al., 2006). Cancer-related depression and
anxiety symptoms decreased after psilocybin assisted therapy as
measured by the Beck Depression Inventory, Hospital Anxiety and
Depression Scale, State-Trait Anxiety Inventory metrics in a doubleblind, placebo-controlled clinical trial (Ross et al., 2016). Further,
decreases in psychological distress and anxiety about cancer
related death post psilocybin assisted therapy were observed in a
randomized, double-blind, cross-over trial utilizing a 17-item
GRID-Hamilton Depression Rating Scale (GRIDHAM-D-17) and
Hamilton Anxiety Rating Scale (HAM-A) (Grifﬁths et al., 2016).
Results of psilocybin ingestion outside of clinical trials have also
been described throughout the literature. These include increased
connection to nature, enhanced creativity and greater enjoyment of
music (Riley and Blackman 2008). Psilocybin ingestion increased
positive mood, attenuated recognition of negative facial expressions, increased goal-directed behavior toward positive cues, and
facilitated positive emotional effects in a randomized double-blind
study (Kometer et al., 2012). In an additional study psilocybin
consumption induced decreases in amygdala activity correlated
with positive mood (Kraehenmann et al., 2015).
The effects of psilocybin consumption has also been found to alter
temporal processing (Wittmann et al., 2006), and brain region connectivity via blood ﬂow patterns (Carhart-Harris et al., 2017; Johnson
et al., 2019; Lebedev et al., 2015; Tagliazucchi et al., 2014). Psilocybin
has been found to alter activation of different areas of the brain when
participants were asked to recall memories (Carhart-Harris et al.,
2012b), and to be associated with decreases in cerebral blood ﬂow
and blood oxygen level dependent signaling (Carhart-Harris et al.,
2012a). This led authors to suggest psychoactive effects may be due
to decreased activity and connectivity of some brain regions (CarhartHarris et al., 2012a). Cerebral blood ﬂow also showed post-treatment
decrease in the temporal cortex including the amygdala in patients
with treatment -resistant depression, which was correlated with
reduced depressive symptoms (Carhart-Harris et al., 2017). Further
studies showed that plasma psilocybin level is correlated with functional connectivity reﬂected in network integrity and network
segregation (Madsen et al., 2021). An association between “egodissolution” and decreased interhemispheric communication has
also been reported (Lebedev et al., 2015). It has been postulated that
neuroplasticity may be responsible for psilocybin's therapeutic effects (Banks et al., 2021).

columns (non-polar stationary phase and polar mobile phase) can
be used to promote psilocybin and psilocin column migration and
simultaneous separation of nonpolar contaminants (Stebelska
2016). Altering column length and size, types of SPE columns, and
polarity of phases have been used to optimize chromatographic
separation of psilocybin, psilocin, and other compounds
 et al., 2021; Nagy and Veress 2016; Ra
cz et al., 2019;
(Gotvaldova
Veress et al., 2019).
Quantitative psilocybin and psilocin detection methods involve
gas chromatography, high-performance liquid chromatography, or
ultra-high performance liquid chromatography methods and can
be combined with mass spectrometers (Stebelska 2016). Molecules
of interest are ionized (become charged), then are separated via a
magnetic ﬁeld based on their mass-to-charge ratios (m/z) and the
resulting mass signal intensities can be used to precisely identify
psilocybin, psilocin, and potential contaminants in each sample.
Quantiﬁcation of psilocybin and related compounds is achieved by
comparing experimental values to a known concentration range of
pure analytes as reference standards or internal standards, sometimes with isotopic substitutions for unique distinction from the
mass of interest (e.g., psilocybin-D6, with six deuterium isotope
substitutions). Other methods of analytical detection and qualitative, semi-quantitative, or quantitative analysis include: spectroscopic techniques (UVeVis, IR), thin-layer chromatography, and ion
mobility spectrometry (Stebelska 2016). These technologies can be
readily adapted for detection of contaminants in fungal products
and or extracts including residual solvents from extractions, microbial contaminants, and disinfectants from cultivation (Chang
et al., 2014; Du et al., 2018; Gałgowska and Pietrzak-Fiecko 2017;
Lambert 1938; Moore 2005; Stamets and Chilton 1983; Tian et al.,
2020).
5. Therapeutic psilocybin usage
Indigenous practices have pioneered and established the notion
of individual and group psilocybin therapies (Echevarría 1979;
Heim and Wasson 1958; Wasson 1957). Various Mesoamerican
cultures, in particularly the Mazatec people, have employed ritualistic elements and guidance facilitated by curandero(a)s to prepare individuals for the sacrament of taking psilocybin mushrooms.
These rituals were and are undertaken to provide new perspectives
on mental and emotional health, conﬂicts, and to resolve social
dysfunction, trials, and tribulations (Echevarría 1979; Heim and
Wasson 1958; Wasson 1957). To provide a positive experience, a
mainstay practice for generations of indigenous people has been to
place emphasis on competent, experienced, and genuine guides.
These guides can ensure that environmental and personal factors,
or what is currently described as set and setting, are favorably
aligned.
The indigenous knowledge that psilocybin experiences have
high therapeutic potential has been mirrored in recent, western,
medicalized psilocybin clinical trials, which have conﬁrmed the
importance of preparation, set and setting (e.g.,Carhart-Harris et al.,
2018; Horton et al., 2021; Roseman et al., 2018). In addition, the
beneﬁts of group-based therapies (Anderson et al., 2020) and
having a guiding therapist performing a curandero(a)-like role have
been quantiﬁed (Horton et al., 2021).
There are currently over 60 ongoing psilocybin clinical trials
overseen by the United States National Institute of Health. Given
that many psilocybin clinical trials are in early phases, explicit longterm medical effectiveness in treating mental health conditions are
yet to be determined in the western framework. Even so, preliminary data suggest psilocybin therapies are effective in treating
depression (e.g. Carhart-Harris et al., 2017; Goldberg et al., 2020;
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with expert evaluation of salient micro- and macromorphological
features and is paramount to safe use of mushrooms and products
thereof.

6. Potential risks of psilocybin usage
While potential beneﬁts of psilocybin are striking, adverse
physiological and psychological reactions to consuming psilocybin
mushrooms have been documented and reviewed (Andersson
et al., 2008; Johnson et al., 2019; Oregon Psilocybin Evidence
Review 2021). In a recent large scale clinical trial of 233 patients,
179 reported headache, nausea, fatigue, or insomnia, and concerningly 12 patients showed suicidal behavior, intentional selfinjury, and suicidal ideation (COMPASS Pathways 2021). Other
studies have reported potential risks of ingesting psilocybin
containing-mushrooms to include short lived panic, anxiety, and
paranoia (Hasler et al., 2004; Musha et al., 1986; Riley and
Blackman 2008), hypertension, tachycardia, hyperreﬂexia, mydriasis, paresthesia, and feelings of depersonalization (Peden et al.,
1982), renal and gastrointestinal complications (Austin et al.,
2019), and hallucinatory sensations (Satora et al., 2005). In clinical settings, safety guidelines have been instated to manage
adverse reactions (Johnson et al., 2008). It is unclear to what extent
side effects reported when mushrooms were consumed are due to
the presence of other co-occurring compounds. For example,
phenylethylamine, which is associated with tachycardia, nausea,
and anxiety, has been reported in Psilocybe semilanceata (Beck et al.,
1998). The presence of other bioactive compounds including psilocybin biosynthetic pathway intermediates (Beug and Bigwood
1982; Fricke et al., 2019b; Sherwood et al., 2020; van Amsterdam
et al., 2011) may also be associated with some of these effects.
In addition, unknown bioactive compounds in Psilocybe species
may pose a risk for consumers. Some species (Psilocybe azurescens,
Psilocybe subaeruginosa, and other species that grow on decaying
wood) are believed to be capable of inducing a temporary paralytic
state, colloquially known as “wood lovers’ paralysis”. This phenomenon has been mentioned anecdotally in formal literature
(Sherwood et al., 2020), and may have been described in a report of
temporary paralysis and hallucination in Japan (Imai 1932). While
this phenomenon is not yet documented in the primary literature,
extreme care should be taken to avoid adverse reactions by consumption of these species.
Combining psilocybin with other substances can also cause
striking adverse reactions in some individuals. Fatalities reported in
connection with the consumers of psilocybin mushrooms often
involve alcohol and other drugs (Andersson et al., 2008; van
Amsterdam et al., 2011). Hallucinogen persisting perception disorder has also been reported in a case study where Psilocybe
mushrooms were consumed with alcohol and cannabis (Skryabin
et al., 2018). Ingestion of mushrooms may also be associated with
exacerbation of some underlying mental health conditions
(Johnson et al., 2019; Nielen et al., 2004). Other risks of consuming
fungal products, in general, include allergic reactions or potential
gastrointestinal distress for sensitive consumers.
Consuming misidentiﬁed fungi can cause severe adverse reactions for consumers, including death. The majority of psilocybin
and psilocin producing mushrooms have a similar appearance to
mushrooms that produce potent toxins, and misidentiﬁcation can
lead to fatalities (Lincoff and Mitchel 1977). Notably, several species
of Galerina produce cyclopeptides including amatoxins that
permeate the liver and kidneys and inhibit DNA-dependent RNA
polymerase B. By disrupting mRNA transcription, amatoxins cease
protein synthesis, resulting in cell necrosis (Horowitz and Moss
2021; Wieland et al., 1981). Potential harms of ingesting misidentiﬁed fungi include acute or delayed gastrointestinal distress,
hypotension, tachycardia, coagulopathy, liver and kidney damage,
autonomic and central nervous system malfunction, and/or death
(Franz et al., 1996; Lincoff and Mitchel 1977). Accurate identiﬁcation of fungi to species often requires DNA sequencing combined

7. Currently available diagnostics
Diagnostics have been developed for detection psilocybin and
psilocybin. In the body these include analysis of psilocybin content
in hair (Pichini et al., 2014), urine (Bambauer et al., 2021; Kamata
et al., 2005; Poliwoda et al., 2020; Shoda et al., 2011), or in blood
€ferstein 2000). Procedures to identify Psiloplasma (Sticht and Ka
cybe mushrooms and products have also been developed (Gambaro
et al. 2015, 2016). Methods for detection include enzyme-linked
immunosorbent assays (ELISAs) via monoclonal antibodies that
bind psilocybin or psilocin (Morita et al., 2020), liquid or gas
cz et al., 2019; Saito et al.,
chromatography (Kamata et al., 2005; Ra
2005), and mass spectrometry (Pichini et al., 2014). It is possible to
differentiate between psilocybin, psilocin, and related molecules

using hydrophilic interaction liquid chromatography (Gotvaldova
cz et al., 2019).
et al., 2021; Ra
There are also ﬁeld-based mushroom diagnostic kits that enable
affordable, rapid, sensitive, and accurate detection of fungal substances and identities (Gao et al., 2021; He et al., 2019b; St John and
Price 2014; Wang et al., 2021). These kits employ a range of technologies including nucleic acid ampliﬁcation, antibody detection via
immunoassay, and chemical detection via chromatography (Bever
et al., 2020; St John and Price 2014). Non-laboratory-based assays
are critical to harm reduction as they enable species identiﬁcation
veriﬁcation and dosage determination. Currently, there are ﬁeld
based kits available for quantiﬁcation of psilocybin (Miraculix, Jena,
Germany) and detection of amatoxin, the cyclopeptide toxin found
in many deadly mushrooms including Galerina marginata (Bever
et al., 2020) which is morphologically similar to several Psilocybe
species, such as Psilocybe allenii and Psilocybe cyanescens.
8. Necessary research and technological advancements
Genetic and genomic data are essential tools necessary to identify, study, and utilize fungi in applied efforts, and as such the need
for research on fungal genomics and biology cannot be underscored
enough. Utilizing modern DNA sequencing-based approaches will
enable an understanding of population-level diversity and its conservation. Further, the generation of genome sequences will facilitate
evaluation of how evolutionary and potentially anthropogenic selective pressures have affected psilocybin biosynthetic gene clusters
including sequence and copy number variation, gene orientation,
and elucidation of novel function. Last, such resources will allow a
better understanding of the species diversity in Psilocybe and other
psilocybin producing fungi.
Diagnostic development is crucial for safe and effective applied
fungal biological efforts. While current diagnostic kits described
above allow for identiﬁcation of psilocybin and amatoxins, only the
Miraculix kit, which conﬁrms the presence and quantity of psilocybin, is available to consumers. Preliminary research has shown
psilocybin containing species from Inocybe (Kosentka et al., 2013)
and Galerina (Gartz 1995) that have been analyzed so far do not
contain the same toxins as their close relatives. However, given the
repercussions of fungal toxin poisoning and wide diversity of
uncharacterized fungal species, a robust multiplex assay that can
differentiate psilocybin-containing genera is desired. While presence of psilocybin is a good indicator that the tested sample is not a
misidentiﬁed toxic mushroom, there is a need for ﬁeld-deployable
identiﬁcation kits that compare toxin presence as well.
Understanding the molecular basis for adverse reactions to
fungal consumption including “wood lover's paralysis” (WLP) is
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high research priority. While no references are currently available
in the research literature, numerous anecdotal reports describe
short term (less than 24 h) paralysis and other WLP symptoms
4e6 h post ingestion of P. azurescens, P. cyanescens, and
P. subaeruginosa, amongst others. Temporary paralysis carries
situational hazards such as hypothermia, heat-stroke, drowning,
and trauma. There have been very few documented deaths in the
peer-reviewed literature associated with the consumption of
psilocybin-containing mushrooms including the wood lovers, and
in all references, confounding factors are noted (van Amsterdam
et al., 2011). Gaining insight into the origins and molecular mechanisms of WLP will guide safe and effective interfacing between the
public and fungi.
At present, there is a limited understanding of fungal biology
including psilocybin-producing fungal species in the public, and an
accompanying under representation of diverse peoples and
knowledge in both applied and academic mycology. Education and
outreach efforts are central to diversifying mycological communities and encouraging citizen scientists’ contributions to mycological progress. Promoting awareness of fungal biology and
ecology promotes public health by equipping populations to
identify and avoid consumption of toxic or poisonous fungi, and to
utilize fungi in novel application development.
The goal to increase fungal biological knowledge in all communities can be pursued by creating modernized educational materials and utilizing digital resources such as iNaturalist. Engaging
the public with citizen science efforts such as documenting fungal
diversity results in large and powerful datasets. For example,
because only a fraction of fungal species diversity is currently
described (Hawksworth and Lücking 2017; James et al., 2020) tools
such as iNaturalist harness the power of citizen science to better
understand fungal biology and distributions. This knowledge in
turn better informs science-based policy development.
We can begin to address the lack of diversity in mycology
through the integration of fungal biology modules into childhood
and K-12 curricula, as well as diversifying equitable educational
materials such as open access publications, audio and video recordings, and visual digital platforms. Increasing the diversity of
peoples involved in all aspects of mycology ensure equitable and
just adoption of psilocybin use. Development of therapeutic practices must be tested across a range of participants, including those
from traditionally marginalized groups.
Lastly, ﬁnancial gain from psilocybin therapies must be examined and knowledge keepers compensated. After Gordon Wasson
introduced psilocybin mushrooms to the wider world, and violated
his commitment to secrecy by exposing the identity of María
Sabina, multiple patents were put forward based on compounds
from Psilocybe mushrooms without any planned compensation for
indigenous communities (Gerber et al., 2021). Protection of indigenous intellectual property rights and just compensation are
needed as psilocybin products are developed, to not continue the
history of large pharmaceutical companies proﬁting off indigenous
knowledge without adequate compensation (McGonigle 2016).

Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.funbio.2022.01.003.
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